Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma

Ashutosh D. Wechalekar, C. I. Chen, D. Sutton, D. Reece, M. Voralia, A. K. Stewart

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Fingerprint

Dive into the research topics of 'Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma'. Together they form a unique fingerprint.

Medicine & Life Sciences